How have ENLV and FEMY total returns compared?

Over the past 5 years, ENLV delivered -69.81% and FEMY delivered -57.27% annualized total return. Past performance doesn't predict future results.

Enlivex Therapeutics Ltd. (ENLV) vs Femasys Inc. (FEMY)

A side-by-side comparison of Enlivex Therapeutics Ltd. and Femasys Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ENLV

Enlivex Therapeutics Ltd.

$6M

$0.34HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

FEMY

Femasys Inc.

$6M

$2.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ENLV vs FEMY

growth of $100 · dividends reinvested · last 5y

ENLV -99.7% (-69.7%/yr)FEMY -99.2% (-61.5%/yr)FEMY compounded faster over this window

ENLV FEMY

ENLV vs FEMY: by the numbers

•FEMY is the larger company ($6M vs $6M market cap).
•Both run net losses; ENLV's is the smaller (0.00% vs -534.27% net margin).

Metrics side by side

Valuation

Metric	ENLV	FEMY
P/E ratio	0.00	N/A
P/S ratio	N/A	2.73
P/B ratio	0.00	1.56

Profitability

Metric	ENLV	FEMY
Gross margin	0.00%	61.96%
Operating margin	0.00%	-763.90%
Net margin	0.00%	-534.27%
ROE	105.35%	-304.78%
ROIC	-0.32%	-209.05%

Growth (annualized)

Metric	ENLV	FEMY
Revenue CAGR (5Y)	N/A	12.97%
Total return CAGR (5Y)	-69.81%	-57.27%

Frequently asked

How have ENLV and FEMY total returns compared?: Over the past 5 years, ENLV delivered -69.81% and FEMY delivered -57.27% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ENLV analysis Full FEMY analysis Interactive comparison tool

Dig into the metrics

Enlivex Therapeutics ROE Femasys ROE Enlivex Therapeutics operating margin Femasys operating margin Enlivex Therapeutics revenue growth Femasys revenue growth Enlivex Therapeutics free cash flow Femasys free cash flow

Enlivex Therapeutics & Femasys appear in these rankings

Highest ROE Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.